Login to Your Account



EHA YEEHA DUE AS WELL

Data 'selectin' probable ASCO winners; Glycomimetics AML biomarker distinct

By Randy Osborne
Staff Writer

Friday, May 19, 2017

As abstracts rolled out for next month's American Society of Clinical Oncology (ASCO) meeting in Chicago, Glycomimetics Inc. whetted the appetite for more data from an ongoing phase II trial with E-selectin antagonist GMI-1271 in acute myeloid leukemia (AML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription